CME credits: 0.25

Valid until: 28-09-2019

Claim your CME credit at https://reachmd.com/programs/cme/opioid-use-disorder-expanding-access-to-treatment/10410/

Opioid use disorder is a growing problem in the United States. Every day we hear about the rampant increase in the misuse of prescription analgesics, the easy accessibility of opioids, and the skyrocketing opioid overdoses that demonstrate the need for healthcare providers to not only understand more about these drugs, but also offer meaningful treatments.

CME credits: 0.50

Valid until: 30-11-2019

Claim your CME credit at https://reachmd.com/programs/cme/a-multi-professional-approach-to-driving-clear-results-for-rosacea-a-case-based-discussion/10384/

Rosacea is a common chronic disorder that affects as much as 10 percent of the population. This cutaneous disease is highly distressful to patients, as it can have ocular manifestations that come with a risk of vision loss. It is also associated with many comorbidities that are too often overlooked by practitioners. This case review activity will explore three very different patients and how a team of clinicians can work together to achieve clear skin.

CME credits: 0.25

Valid until: 28-09-2019

Claim your CME credit at https://reachmd.com/programs/cme/precision-oncology-incorporating-next-generation-sequencing-ngs-nsclc/10412/

Non-small cell lung cancer (NSCLC) is a leading cause of cancer death in the United States. Identification of targetable mutations has led to the development of therapies and improvements in NSCLC patient outcomes. However, many patients continue to experience poor survival due to suboptimal genomic profiling and treatment. In this activity, we will evaluate the advantages of NGS testing platforms and companion diagnostics over the conventional genomic profiling approach and discuss strategies to overcome barriers to wide adoption in community oncology settings.

Dr. Joshua Bauml is joined by Dr. Timothy McCarthy to discuss incorporating NGS in NSCLC.

CME credits: 0.25

Valid until: 28-09-2019

Claim your CME credit at https://reachmd.com/programs/cme/rheumatoid-arthritis-counseling-women-who-are-trying-conceive/10403/

Rheumatoid arthritis, or RA, affects women three times more frequently than men, often in their childbearing years. Not only does pregnancy affect their disease course, healthcare needs and treatment options, but it also complicates the family planning decisions they are making. This makes the need for better support systems all the more critical for these patients.

Dr. Matt Birnholz is joined by Dr. Robin Dore, Clinical Professor of Medicine at David Geffen School of Medicine at UCLA. Dr. Dore will provide tips on how she counsels her RA patients during their family planning journey.

Host: Matt Birnholz, MD

Guest: Joshua D. Lee, MD

Opioid use disorder is a growing problem in the United States. Every day we hear about the rampant increase in the misuse of prescription analgesics, the easy accessibility of opioids, and the skyrocketing opioid overdoses that demonstrate the need for healthcare providers to not only understand more about these drugs, but also offer meaningful treatments.

CME credits: 0.25

Valid until: 27-09-2019

Claim your CME credit at https://reachmd.com/programs/cme/trading-places-future-mis-outpatient-setting-and-future-now/10411/

The ability to perform in-office minimally invasive procedures (MIS) has revolutionized the approach to abnormal uterine bleeding in women, giving them options for fast trauma-free assessment and management of their complaints. However, nearly 150 years after the first hysteroscopic procedure, MIS are still most commonly performed in the hospital setting, increasing the cost of care and causing avoidable delays in management due to the need for multiple appointments.

This activity will examine practical strategies to address the current barriers that OB/GYNs face when setting up in-office MIS and address why more aren’t being performed in the community setting.

CME credits: 0.50

Valid until: 24-09-2019

Claim your CME credit at https://reachmd.com/programs/cme/moving-toward-a-new-standard-of-care-checkpoint-inhibitors-in-advanced-urothelial-cancer/10347/

Urothelial cancer of the bladder, renal pelvis, ureter, and other urinary organs is the fifth most common cancer in the United States, and systemic platinum-based chemotherapy remains the standard of care for first-line treatment of advanced/metastatic urothelial carcinoma (UC). Until recently, there were limited options for patients who are refractory to chemotherapy, or do not tolerate chemotherapy due to toxicities and overall outcomes have remained very poor. Standard salvage systemic therapies for advanced/metastatic UC, and chemotherapy regimens were associated with modest survival advantage, and significant toxicities; however, the introduction of novel immunotherapy agents has led to rapid changes in the field of UC.

Dr. John Russell, Director of the Family Medicine Residency at Abington Memorial Hospital, is joined by Dr. Arjun V. Balar, Associate Professor of Medicine and the Director of the Genitourinary Medical Oncology Program at the Laura and Isaac Perlmutter Cancer Center at New York University Langone Medical Center.

Host: Rishi P. Singh, MD

Guest: Arshad Khanani, MD

Guest: Ehud Ur, MD

Guest: David Boyer, MD

Therapeutic options for the treatment of DR and DME have expanded, and advancements in medical imaging technologies provide a wider scope of options for efficient, accurate and reproducible diagnosis and monitoring of ocular conditions. Likewise, diabetes management guidelines and strategies, including pharmacologic treatments and devices, have also evolved, underscoring the importance of cross-disciplinary education and communication, as well as a higher level of participation from the patient. Treatment and management strategies need to be determined that lower the burden of illness, lower the burden of treatment, and enhance outcomes and overall quality of life for patients.

CME credits: 1.00

Valid until: 25-09-2019

Claim your CME credit at https://reachmd.com/programs/cme/the-p4-approach-revolutionizing-diabetic-macular-edema/10370/

Therapeutic options for the treatment of DR and DME have expanded, and advancements in medical imaging technologies provide a wider scope of options for efficient, accurate and reproducible diagnosis and monitoring of ocular conditions. Likewise, diabetes management guidelines and strategies, including pharmacologic treatments and devices, have also evolved, underscoring the importance of cross-disciplinary education and communication, as well as a higher level of participation from the patient. Treatment and management strategies need to be determined that lower the burden of illness, lower the burden of treatment, and enhance outcomes and overall quality of life for patients.

CME credits: 0.25

Valid until: 25-09-2019

Claim your CME credit at https://reachmd.com/programs/cme/promising-bifunctional-agents-in-immuno-oncology-a-roundtable-discussion-with-the-experts/10165/

The presence of transforming growth factor-beta (TGF-β) in the tumor microenvironment plays a main role in limiting the clinical efficacy of anti-PD-1/PD-L1 checkpoint inhibitors. Not only does TGF-β suppress the normal anti-tumor action of natural killer cells and T cells, but it is also involved in many processes of cancer progression and metastasis, such as fibroid cap formation, epithelial-to-mesenchymal transition, and angiogenesis.

This panel will discuss the latest findings in the role of TGF-β in tumor formation and progression, as well as treatment advances that target PDL1 and TGF-β pathways simultaneously.

For more episodes in this series, visit ReachMD.com/IO.